SCHEMBL279987

SCHEMBL279987

Cc1ccc(C(=O)NN(C)C)s1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.54
POLB P06746 1/20 0.54
TDP1 Q9NUW8 1/20 0.54
DAO P14920 1/20 0.53
NPC1 O15118 11/20 0.50
RAB9A P51151 11/20 0.50
MEN1 O00255 3/20 0.50
TAS1R3 Q7RTX0 1/20 0.50
TAS1R1 Q7RTX1 1/20 0.50
ALDH1A1 P00352 6/20 0.48
GAA P10253 1/20 0.48
SMN1; SMN2 Q16637 6/20 0.47
LMNA P02545 4/20 0.47
USP2 O75604 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
TP53 P04637 1/20 0.44
HPGD P15428 1/20 0.44
HSD17B10 Q99714 1/20 0.44
KDM4E B2RXH2 1/20 0.43
MAPT P10636 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14395878 0.81 KDM4E (0.50) KMT2APOLBTDP1NPC1RAB9A
SCHEMBL12124464 0.79 DAO (0.61) KMT2APOLBTDP1DAONPC1
SCHEMBL12265915 0.79 ALDH1A1 (0.50) KMT2APOLBTDP1NPC1RAB9A
SCHEMBL7967944 0.78 KMT2A (0.59) KMT2APOLBTDP1DAONPC1
SCHEMBL280057 0.77 RAB9A (0.52) KMT2APOLBTDP1DAONPC1
SCHEMBL13006694 0.77 HPGD (0.37) KMT2APOLBTDP1DAONPC1
SCHEMBL12265885 0.77 RAB9A (0.55) KMT2APOLBTDP1DAONPC1
SCHEMBL279582 0.76 KMT2A (0.62) KMT2APOLBTDP1DAONPC1
SCHEMBL6375945 0.76 KMT2A (0.53) KMT2APOLBTDP1DAONPC1
SCHEMBL16674874 0.74 KMT2A (0.56) KMT2APOLBTDP1DAONPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8134013-B2 Amide compound and thrombopoietin receptor activator NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2012-03-13 US disclosed
US-8134013-B2 Amide compound and thrombopoietin receptor activator NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2012-03-13 US disclosed
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2009-05-21 US disclosed
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2009-05-21 US disclosed
EP-1845090-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR Nissan Chemical Industries, Ltd. (JP) 2007-10-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR TEK, PTAFR, MPL KMT2A 3398/4885POLB 4352/4885TDP1 2969/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.